GSK

GSK dials up HIV sales projection to £7B by 2026, updates next-gen launch timelines
GSK dials up HIV sales projection to £7B by 2026, updates next-gen launch timelines
Fierce Pharma
GSK
HIV
Cabenuva
ViiV Healthcare
Flag link:
In pleasant surprise for GSK, FDA approves Jakafi challenger Ojjaara in broad blood cancer use
In pleasant surprise for GSK, FDA approves Jakafi challenger Ojjaara in broad blood cancer use
Fierce Pharma
GSK
FDA
Ojaara
momelotinib
myelofibrosis
Flag link:
AstraZeneca, working to grow Fasenra’s reach, touts positive trial against GSK's Nucala in new use
AstraZeneca, working to grow Fasenra’s reach, touts positive trial against GSK's Nucala in new use
Fierce Pharma
AstraZeneca
Fasenra
clinical trials
GSK
Nucala
eosinophilic asthma
Flag link:
AstraZeneca’s Fasenra meets primary endpoint in Phase III rare vasculitis trial
AstraZeneca’s Fasenra meets primary endpoint in Phase III rare vasculitis trial
Clinical Trials Arena
AstraZeneca
Fasenra
GSK
Nucala
eosinophilic granulomatosis with polyangiitis
clinical trials
Flag link:
GSK spends big on new RSV vax commercials, but it's an AbbVie clean sweep as August's top pharma drug ad spender
GSK spends big on new RSV vax commercials, but it's an AbbVie clean sweep as August's top pharma drug ad spender
Fierce Pharma
AbbVie
GSK
DTC advertising
pharma marketing
Flag link:
Patent cliffs, divestitures and maturing biotechs all point to more pharma M&A: analysts
Patent cliffs, divestitures and maturing biotechs all point to more pharma M&A: analysts
Fierce Pharma
M&A
patent cliffs
Merck
JNJ
Pfizer
GSK
Novartis
Eli Lilly
Novo Nordisk
Flag link:
GSK Invests $272 Million in New Vaccine Manufacturing Unit for Production of Shingles and RSV Vaccines
GSK Invests $272 Million in New Vaccine Manufacturing Unit for Production of Shingles and RSV Vaccines
Xtalks
GSK
Belgium
vaccines
drug manufacturing
Flag link:
5 of the best places to work in pharma, according to employees
5 of the best places to work in pharma, according to employees
Pharma Voice
Glassdoor
Merck
JNJ
Pfizer
GSK
Sanofi
Flag link:
GSK, Moderna fight over ‘COVID MVAX’ trademark. What does it mean for pharma?
GSK, Moderna fight over ‘COVID MVAX’ trademark. What does it mean for pharma?
Medical Marketing and Media
GSK
Moderna Therapeutics
trademark
vaccines
COVID-19
Flag link:
In GSK's trial of shingles vaccine in China, Shingrix keeps it 100
In GSK's trial of shingles vaccine in China, Shingrix keeps it 100
Fierce Pharma
GSK
vaccines
shingles
Shingrix
China
Flag link:
Malaria vaccine-drug combo achieves 'dramatic' results
Malaria vaccine-drug combo achieves 'dramatic' results
Pharmaphorum
GSK
Mosquirix
malaria
vaccines
clinical trials
Flag link:
GSK stays a step ahead in RSV vaccine battle as Arexvy becomes available at US pharmacies
GSK stays a step ahead in RSV vaccine battle as Arexvy becomes available at US pharmacies
Fierce Pharma
GSK
RSV
vaccines
Arexvy
Pfizer
Moderna Therapeutics
Flag link:
The 10 drugs that CMS might wrangle into negotiations
The 10 drugs that CMS might wrangle into negotiations
Beckers Hospital Review
CMS
Medicare
drug pricing
Bristol Myers Squibb
Janssen
Merck
Pfizer
Amgen
Boehringer Ingelheim
Pharmacyclics
AstraZeneca
Astellas
GSK
Flag link:
GSK Sues Pfizer for Alleged RSV Vaccine Patent Infringement
GSK Sues Pfizer for Alleged RSV Vaccine Patent Infringement
BioSpace
GSK
Pfizer
RSV
vaccines
legal
Patent Infringement
Flag link:
GSK beats Merck to first PD-1 approval in newly diagnosed endometrial cancer
GSK beats Merck to first PD-1 approval in newly diagnosed endometrial cancer
Fierce Pharma
GSK
FDA
immunotherapy
endometrial cancer
Jemperli
Flag link:
Big Pharma CEOs get candid about pricing and M&A
Big Pharma CEOs get candid about pricing and M&A
Pharma Voice
Big Pharma
Pharma CEOs
drug pricing
M&A
JNJ
Merck
GSK
Flag link:
GSK Expects Slower Uptake of RSV Vaccine Amid Record Sales for Shingles Shot
GSK Expects Slower Uptake of RSV Vaccine Amid Record Sales for Shingles Shot
BioSpace
GSK
earnings
vaccines
RSV
Arexvy
Flag link:
J&J, GSK's ViiV tout switching study showing patients prefer their long-acting HIV med Cabenuva over Gilead rival
J&J, GSK's ViiV tout switching study showing patients prefer their long-acting HIV med Cabenuva over Gilead rival
Fierce Pharma
JNJ
GSK
ViiV
Gilead Sciences
HIV
Cabenuva
Biktarvy
Flag link:
Pfizer, Gilead, GSK to Capture Growing Infectious Diseases Market as J&J Pulls Back
Pfizer, Gilead, GSK to Capture Growing Infectious Diseases Market as J&J Pulls Back
BioSpace
infectious diseases
Pfizer
Gilead Sciences
GSK
JNJ
Flag link:
GSK Returns Shigella Vaccine Candidate to LimmaTech as Drug-Resistant Cases Rise
GSK Returns Shigella Vaccine Candidate to LimmaTech as Drug-Resistant Cases Rise
BioSpace
GSK
vaccines
Shigella
LimmaTech
Flag link:

Pages